PositoAI/ US/ INmune Bio Inc.

INmune Bio Inc.

NasdaqCM: INMB · Healthcare

Positivity Index

#3,715 / 6,775

Global

#1,653 / 4,000

United States

Positivity Score

20,348

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

INmune Bio Inc. — Overview & Financial Snapshot

INmune Bio Inc. (NasdaqCM: INMB) is a Healthcare company, ranked #3,715 of 6,775 companies globally and #1,653 of 4,000 in United States on PositoAI, with a Positivity Score of 20,348. Its market capitalisation is ₹403.43 Cr ($42.74M), P/E ratio is -2.3 and P/B ratio is 2.10. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

P/B Ratio 2.10

P/E Ratio -2.3

D/E Ratio 0.07

ROE -74.82%

Owes vs Owns ? 0.24× Low $0.24 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-63.24$-0.67

Forward EPS ₹-40.59$-0.43

Beta 0.90

Market Cap ₹403.43 Cr$42.74M

What these numbers mean →

What does INmune Bio Inc. do?

What is INmune Bio Inc.'s P/E and P/B ratio?

INmune Bio Inc. has a P/E ratio of -2.3 and a P/B ratio of 2.10.

What is INmune Bio Inc.'s debt-to-equity ratio?

INmune Bio Inc. has a debt-to-equity ratio of 0.07.

How much does INmune Bio Inc. owe compared with what it owns?

INmune Bio Inc. owes $0.24 for every $1 it owns (balance sheet Jun 2026), which is low.

What is INmune Bio Inc.'s Positivity rank?

INmune Bio Inc. is ranked #3,715 of 6,775 companies globally and #1,653 of 4,000 in United States on PositoAI, with a Positivity Score of 20,348.

Does INmune Bio Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for INmune Bio Inc..

Where can I read the latest news about INmune Bio Inc.?

Recent headlines about INmune Bio Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does INmune Bio Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of INmune Bio Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.